|
[1]MOOSAVY SH, DAVOODIAN P, NAZARNEZHAD MA, et al.Epidemiology, transmission, diagnosis, and outcome of hepatitis Cvirus infection[J].Electr Physic, 2017, 9 (10) :5646-5656.
|
|
[2]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[3]MOROZOV VA, LAGAYE S.Hepatitis C virus:Morphogenesis, infection and therapy[J].World J Hepatol, 2018, 10 (2) :186-212.
|
|
[4]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2018[J].J Hepatol, 2018, 69 (2) :461-511.
|
|
[5]HUANG Y, LI MH, HOU M, et al.Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals[J].Hepatobiliary Pancreat Dis Int, 2017, 16 (5) :470-479.
|
|
[6]SPENGLER U.Direct antiviral agents (DAAs) -A new age in the treatment of hepatitis C virus infection[J].Pharmacol T-her, 2018, 183:118-126.
|
|
[7]BROWN A, HEZODE C, ZUCKERMAN E, et al.Efficacy and safety of 12 weeks of elbasvir±grazoprevir±ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection:The C-SCAPE study[J].J Viral Hepat, 2018, 25 (5) :457-464.
|
|
[8]SPERL J, HORVATH G, HALOTA W, et al.Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin:A phase III randomized controlled trial[J].J Hepatol, 2016, 65 (6) :1112-1119.
|
|
[9]KWO P, GANE EJ, PENG CY, et al.Effectiveness of Elbasvir and Grazoprevir combination, with or without Ribavirin, for treatment-experienced patients with chronic hepatitis C infection[J].Gastroenterology, 2017, 152 (1) :164-175.e164.
|
|
[10]ASSELAH T, REESINK H, GERSTOFT J, et al.Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection:A pooled analysis[J].Liver Int, 2018, 38 (9) :1583-1591.
|
|
[11]CORMAN S, ELBASHA EH, MICHALOPOULOS SN, et al.Costutility of Elbasvir/Grazoprevir in patients with chronic hepatitis Cgenotype 1 infection[J].Value Health, 2017, 20 (8) :1110-1120.
|
|
[12]MAUGHAN A, OGBUAGU O.Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection[J].Expert Opin Drug Metab Toxicol, 2018, 14 (2) :219-227.
|
|
[13]JACOBSON IM, GORDON SC, KOWDLEY KV, et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J].N Engl J Med, 2013, 368 (20) :1867-1877.
|
|
[14]LAWITZ E, MANGIA A, WYLES D, et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl JMed, 2013, 368 (20) :1878-1887.
|
|
[15]KUMADA H, SUZUKI Y, IKEDA K, et al.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection[J].Hepatology, 2014, 59 (6) :2083-2091.
|
|
[16]ZEUZEM S, DUSHEIKO GM, SALUPERE R, et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J].N Engl J Med, 2014, 370 (21) :1993-2001.
|
|
[17]LAWITZ E, SULKOWSKI MS, GHALIB R, et al.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients:The COSMOS randomised study[J].Lancet, 2014, 384 (9956) :1756-1765.
|
|
[18]ZHAO XT, NIE QH.Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C[J].J Clin Hepatol, 2017, 33 (6) :1067-1072. (in Chinese) 赵西太, 聂青和.直接抗病毒药物治疗丙型肝炎的毒副作用、药物相互作用及安全性[J].临床肝胆病杂志, 2017, 33 (6) :1067-1072.
|
|
[19]PREDA CM, POPESCU CP, BAICUS C, et al.Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis[J].Liver Int, 2018, 38 (4) :602-610.
|
|
[20]FOSTER GR, AGARWAL K, CRAMP ME, et al.Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis:A randomized trial[J].Hepatology, 2018, 67 (6) :2113-2126.
|
|
[21]JACOBSON IM, LAWITZ E, KWO PY, et al.Safety and efficacy of Elbasvir/Grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis:An integrated analysis[J].Gastroenterology, 2017, 152 (6) :1372-1382.e1372.
|
|
[22]RAVAIOLI F, CONTI F, BRILLANTI S, et al.Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals[J].Dig Liver Dis, 2018, 50 (6) :573-579.
|
|
[23]CALVARUSO V, CABIBBO G, CACCIOLA I, et al.Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents[J].Gastroenterology, 2018, 155 (2) :411-421.e4.
|
|
[24]European Association for the Study of the Liver.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69 (2) :406-460.
|
|
[25]BELLI LS, DUVOUX C, BERENGUER M, et al.ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients[J].J Hepatol, 2017, 67 (3) :585-602.
|
|
[26]SORIANO V, BARREIRO P, de MENDOZA C, et al.Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis[J].Antivir Ther, 2016, 21 (1) :91-92.
|
|
[27]LIONETTI R, CALVARUSO V, PICCOLO P, et al.Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis:A prospective study[J].Clin Transplant, 2018, 32 (2) :e13165.
|
|
[28]MANNS M, SAMUEL D, GANE EJ, et al.Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease:A multicentre, open-label, randomised, phase 2 trial[J].Lancet Infect Dis, 2016, 16 (6) :685-697.
|
|
[29]CHARLTON M, EVERSON GT, FLAMM SL, et al.Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease[J].Gastroenterology, 2015, 149 (3) :649-659.
|
|
[30]CHENG DY, LIU XM, OU MN, et al.Clinical efficacy of directacting antiviral agents in patients with HCV-related liver cirrhosis[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (6) :545-549. (in Chinese) 程丹颖, 刘晓民, 欧蔚妮, 等.直接抗病毒药物治疗丙型肝炎肝硬化的疗效观察[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (6) :545-549.
|
DownLoad: